Elsibucol
Alternative Names: AGI-1096Latest Information Update: 18 Apr 2013
At a glance
- Originator AtheroGenics
- Class Anti-inflammatories; Butyric acids; Phenols
- Mechanism of Action Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 18 Apr 2013 Discontinued - Phase-I for Transplant rejection in USA (PO)
- 08 Feb 2006 Astellas Pharma and AtheroGenics have extended their agreement to co-develop AGI 1096 for the prevention of transplant rejection
- 08 Feb 2006 Clinical data from a media release have been added to the adverse events section